Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-73763989 + JNJ-56136379
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Combination of JNJ-73763989 and JNJ-56136379 is an investigational regimen for the treatment of chronic hepatitis B virus (HBV) infection. JNJ-73763989 is a liver-targeted, N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) therapeutic that reduces hepatitis B surface antigen (HBsAg) and other HBV proteins through RNA interference, thereby suppressing viral gene expression and replication. JNJ-56136379 (also known as bersacapavir, JNJ-6379) is a capsid assembly modulator (CAM) that inhibits HBV replication by interfering with the proper assembly of the viral capsid. The combination, studied with nucleos(t)ide analogues, is designed to maximize reduction in viral replication and protein burden to improve the chance of functional cure in people with chronic hepatitis B. The regimen has been evaluated in phase 2 studies[1][5][6].
- Other names
- bersacapavir
02
Targets
HBV RNA (Hepatitis B virus RNA)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on JNJ-73763989 + JNJ-56136379.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-73763989 + JNJ-56136379.